^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Halaven (eribulin mesylate)

    i
    Other names: E7389, ER-086526, B1939 mesylate, B-1939, Halichondrin B analog, NSC-707389
    Company:
    Eisai, Knight Therap, Shenzhen Kexing Pharma
    Drug class:
    Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor
    Related drugs:
    5d
    Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results. (PubMed, JTO Clin Res Rep)
    FZEC demonstrated modest antitumor activity, and observed AEs were generally manageable in patients with heavily pretreated NSCLC. NCT03386942.
    P1 data • Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Halaven (eribulin mesylate) • farletuzumab ecteribulin (MORAb-202)
    6d
    A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care (clinicaltrials.gov)
    P3, N=364, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
    New P3 trial
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)
    13d
    MBC-EA: A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates (clinicaltrials.gov)
    P2, N=52, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • Halaven (eribulin mesylate)
    14d
    Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease (clinicaltrials.gov)
    P2, N=90, Recruiting, Delcath Systems Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Melblez Kit (melphalan hepatic delivery system)
    15d
    ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, ALX Oncology Inc. | Phase classification: P1/2 --> P2 | N=80 --> 120 | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Jun 2027 --> Dec 2027
    Phase classification • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • gemcitabine • paclitaxel • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • evorpacept (ALX148)
    26d
    JAZMINE: Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, MedSIR
    New P1/2 trial
    |
    HER-2 positive • HER-2 amplification
    |
    capecitabine • Halaven (eribulin mesylate) • Tukysa (tucatinib) • Ziihera (zanidatamab-hrii)
    26d
    CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors. (PubMed, Clin Cancer Res)
    These clinical and preclinical findings provide rationale for therapies to increase therapeutic index of aPD-1 therapy by diminishing presence of T cell-suppressive myelomonocytic cells to improve outcomes for patients with refractory disease.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Halaven (eribulin mesylate) • Turalio (pexidartinib)
    28d
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=558, Recruiting, BioNTech SE | N=144 --> 558
    Enrollment change • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)
    1m
    Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study. (PubMed, Breast Cancer Res Treat)
    These findings will help guide the development of eribulin-based neoadjuvant chemotherapy for selected TNBC patients. Our exploratory analysis of LC and NLR results may help inform clinical prediction models for eribulin-treated patients.
    Clinical • Journal • BRCA Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    carboplatin • paclitaxel • capecitabine • cyclophosphamide • Halaven (eribulin mesylate)
    1m
    ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies (clinicaltrials.gov)
    P1/2, N=80, Recruiting, ALX Oncology Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD47 (CD47 Molecule)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • gemcitabine • paclitaxel • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • evorpacept (ALX148)
    1m
    Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Fudan University
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Halaven (eribulin mesylate)
    1m
    The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (clinicaltrials.gov)
    P2, N=184, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Mar 2026
    Enrollment open • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate • trastuzumab rezetecan (SHR-A1811)